Main Text
β-Thalassemia is a common, frequently debilitating inherited anemia caused by HBB gene mutations that reduce or eliminate expression of the β-globin subunit of adult hemoglobin (HbA, α2β2)(1). The pathophysiology arises from two major consequences 5 of β-globin deficiency. First, insufficient HbA production reduces red blood cell (RBC) oxygen-carrying capacity, causing tissue hypoxia. Second, unstable free -globin protein generates cytotoxic reactive oxidant species and cellular precipitates that impair the maturation and viability of RBC precursors (resulting in ineffective erythropoiesis) and induce premature lysis of mature RBCs (termed hemolysis)(2-9). Heterozygosity for - 10 globin null mutations (-thalassemia trait) is usually clinically silent but becomes symptomatic with co-inheritance of extra -globin genes (HBA1 or HBA2), which increases the level of free -globin protein (10) (11) (12) (13) . Hence, globin-chain imbalance with accumulation of free -globin is a primary determinant of β-thalassemia pathophysiology.
Normal and β-thalassemic RBC precursors have mechanisms to detoxify excess 15 -globin (reviewed in reference (11) ). Specifically, free -globin is stabilized by the molecular chaperone alpha hemoglobin stabilizing protein (AHSP) (14, 15) and is eliminated by other protein quality-control (PQC) mechanisms, including the ubiquitinproteasome system and autophagy(9). Together, these observations suggest that individuals with β-thalassemia mutations can tolerate a modest pool of free -globin, with 20 pathologies arising only when the level of free -globin exceeds the detoxification capacity of the endogenous protective mechanisms (reviewed in reference (11) ). In this respect, β-thalassemia resembles "protein aggregation disorders," characterized by the accumulation of various toxic protein precipitates in disease-specific target tissues (reviewed in references (9, (16) (17) (18) (19) ). Efforts are underway to treat protein aggregation disorders via the pharmacologic induction of PQC pathways to eliminate relevant unstable proteins (20) (21) (22) (23) ). In the current study, we sought to better define the mechanisms of free -globin clearance by autophagy and to manipulate this pathway in order to treat β-thalassemia.
5
Autophagy is a process that delivers cytoplasmic proteins or organelles to lysosomes for degradation (24) . Numerous forms of autophagy are essential for eukaryotic tissue development, cellular homeostasis, and protection against various stresses(25-28). The major autophagic pathway, termed "macroautophagy" (hereafter referred to as "autophagy"), is a multistep process that envelops cargo to be degraded 10 within a double-membrane vesicle (an autophagosome) that eventually fuses with lysosomes (reviewed in references (24, (29) (30) (31) ). Research by several groups, including ours, indicates that free -globin is degraded by autophagy in β-thalassemia (9, 20, 32).
Here we examined the contributions of two core autophagy proteins, Unc-51-like kinase 1 (ULK1) and ATG5, to disease progression in a mouse model of β-thalassemia. ULK1 15 initiates autophagosome formation by phosphorylating several autophagy proteins in response to cellular stresses and has additional roles in autophagy-independent vesicular transport(33, 34). ATG5 is part of a protein complex that conjugates microtubuleassociated protein 1 light chain 3 beta (Map1LC3b, henceforth referred to as LC3) and related proteins to membrane phosphatidyl serine, creating a scaffold that facilitates 20 cargo recognition and autophagosome maturation (21, 24) . ULK1 and ATG5 are essential for most, but not all, autophagy processes. For example, during RBC formation, ULK1 has a non-redundant role in eliminating mitochondria and ribosomes from reticulocytes, whereas ATG5 is dispensable for these processes(35-37).
We used gene-targeted mice to show that the accumulation of toxic insoluble -globin is inhibited by autophagy that is largely ULK1-mediated and ATG5-independent.
Moreover, activation of ULK1 by the mTORC1 (mechanistic Target Of Rapamycin
Complex 1) inhibitor rapamycin reduced the accumulation of insoluble free -globin and alleviated β-thalassemic phenotypes in mice and in human patient-derived RBC precursors. Our findings provide definitive evidence that autophagy relieves the effects of β-thalassemia mutations by degrading excess -globin, and identify an associated mechanism that can be targeted to develop new therapies.
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Hematopoietic ablation of Ulk1 exacerbates β-thalassemia. To determine whether ULK1 mediates free -globin degradation in β-thalassemia, we introduced a null allele into β-thalassemic mice ( (Fig. 1A) . To examine the hematopoietic cell−intrinsic consequences of ULK1 loss in β-thalassemia, we transplanted embryonic (E) day 14.5 fetal liver cells from
and control strains (CD45.2) into lethally irradiated wild-type (WT) CD45.1 hosts (Fig. 1B) . Donor hematopoietic cell engraftment exceeded 92% after 90 days (Fig.   20 S1A). Loss of Ulk1 exacerbated β-thalassemia, with a 20% reduction in the RBC count (P < 0.0001), and a 2-fold increase in the reticulocyte count (P < 0.0001) to maintain the same level of blood hemoglobin (Hb) (Fig. 1C-E (Fig. 1F) . Loss of ULK1 in Hbb Th3/+ mice also caused increased splenomegaly, bone marrow erythroid precursor hyperplasia, and extramedullary erythropoiesis in spleen and liver (Fig. 1G-H, Fig. S1B -E, and Table   5 S2). Together, these findings show that ULK1 deficiency exacerbates ineffective erythropoiesis and reduces the viability of mature RBCs.
ULK1 loss reduces clearance of free -globin in β-thalassemia. To investigate whether the loss of ULK1-dependent autophagy caused increased accumulation of 10 precipitated -globin, we lysed circulating RBCs and fractionated the contents by centrifugation followed by triton-acetic acid-urea (TAU) gel electrophoresis to resolve the -and β-globin proteins(9). As expected, Hbb Th3/+ RBCs contained insoluble -globin, which was increased approximately 2-fold by the loss of ULK1 (P < 0.001) ( Fig. 2A,B) .
Transmission electron microscopy (TEM) revealed collections of electron-dense material, 15 presumably -globin precipitates, in flow cytometry-purified reticulocytes from β-thalassemic mice, but not in those from control mice (Fig. 2C ). (Fig. 2D) . Moreover, the levels of the autophagy (Fig. 2E) . Thus, the loss of ULK1 increases the accumulation of insoluble -globin and autophagic compartments in β-thalassemia.
ATG5-independent autophagy of -globin clearance in -thalassemia. ATG5 is required for most autophagy processes. However, mitochondria are eliminated from 5 reticulocytes in an ATG5-independent, ULK1-dependent form of autophagy(35-37).
Therefore, we investigated the role of ATG5 in eliminating free -globin. We introduced (Fig. S2C) . However, ATG5 deficiency in Hbb Th3/+ mice had minimal effects on the levels of insoluble -globin (Fig. 3E,F) . Thus, ATG5 mediates some (Fig. 4E,F) . Thus, in β-thalassemia, insoluble free -globin is cleared by autophagy that is ULK1-dependent and ATG5-independent.
Rapamycin increases free -globin clearance and reduces pathologies in β-
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thalassemia via ULK1 activation. mTORC1 inhibits autophagy by phosphorylating ULK1(42-45). Therefore, we tested whether mTORC1 inhibition could ameliorate β-thalassemia by stimulating autophagic clearance of free -globin. Rapamycin (4 mg/kg) was administered intraperitoneally to β-thalassemic and control mice daily for 30 days, followed by necropsy. In vivo drug activity in reticulocytes was confirmed by reduced phosphorylation of the mTORC1 target ribosomal protein S6 (P < 0.001) (Fig. S4A,B) . β-Thalassemic mice treated with rapamycin exhibited numerous indications of reduced RBC pathology, including a 27% increase in RBC count (P < 0.001), a 10% increase in 5 Hb (P < 0.05), a 44% decrease in reticulocyte count (P < 0.001), and an increase in the half-life of circulating RBCs from 6.9 to 12.2 days (P < 0.0001; the normal half-life is 18 days) ( Table S5 ). Importantly, rapamycin had no effect on RBC indices or erythropoiesis in WT or Hbb (Fig. 6C-G) . Together, these studies demonstrate that rapamycin treatment of β-thalassemic mice stimulates ULK1-dependent autophagy to reduce free -globin precipitates, alleviate ineffective erythropoiesis, and extend RBC lifespan.
Rapamycin reduces free -globin in human β-thalassemic erythroblasts. To investigate the therapeutic potential of rapamycin in human β-thalassemia, we treated (Table S6 and Table S7 ). Patient or control CD34 + cells were purified from (Fig. S5C,D) .
Non-denaturing ion-exchange (IE) HPLC identified a free -globin peak in TD and NTD β-thalassemic erythroblasts, but not in control cells (Fig. 7C-F and Fig. S5E,F ).
Rapamycin (10µM or 20µM) or the proteasome inhibitor MG132 was added to day 13 cultures, which contained mid-to late-stage erythroblasts, and -globin accumulation was determined by HPLC 2 days later. As expected, proteasome inhibition by MG132 raised free -globin levels in β-thalassemic erythroblasts and also induced cell death (Fig. 7C-F , and Fig. S6A-D) . In contrast, rapamycin treatment reduced free -globin by 40% and 85% in TD β-thalassemia (P < 0.0001) and NTD β-thalassemic erythroblasts (P < 0.001), respectively, with no deleterious effect on cell survival (Fig. 7C-F and Fig. S6A-D) .
Previous studies indicated that rapamycin could elevate fetal hemoglobin level in cultures 5 of erythroblasts derived from human CD34 + cells(47, 48), even if we did not observe this effect in our studies (Fig. S6E) . Thus, rapamycin reduces the accumulation of free -globin in primary erythroid cells derived from patients with β-thalassemia, most likely by inhibiting mTORC1, with consequent derepression of ULK1-mediated autophagy.
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Discussion. We show that ULK1-dependent autophagy of free -globin reduces ineffective erythropoiesis and improves RBC viability in -thalassemia and that this process can be stimulated by the mTORC1 inhibitor rapamycin in mice and in human erythroid cells. Our findings are consistent with the longstanding concepts that globin protein imbalance with excessive build-up of toxic free -chain is a major determinant of 15 β-thalassemia severity(49) and that -thalassemia can be classified as a "protein aggregation disorder" in which disease severity is modulated by PQC activities including the ubiquitin-proteasome system and autophagy (11) . The identification of ULK1 as a central regulator of free -globin autophagy elucidates further our understanding of -thalassemia and highlights a "druggable" pathway that can be leveraged therapeutically.
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Free -globin clearance in erythroid cells is summarized in our current model. In -thalassemia, unpaired -chains are polyubiquitinated and subsequently degraded by the proteasome. The erythroid-specific ubiquitin ligase UBE20 ubiquitinates free -globin , which is consistent with cross-regulation between the UPS and autophagy pathways(9, 52). In contrast, our current findings show that the UPS does not compensate 5 for the loss of ULK1-mediated -globin autophagy, which is consistent with studies demonstrating that autophagy inhibition impairs the degradation of proteasome substrates(53).
Autophagy can occur via multiple mechanisms depending on the physiologic context, cell type, and cargo, with substantial variation in the requirements for specific 10 autophagy proteins (reviewed in reference (24)). Autophagy of free -globin requires ULK1, but not the canonical autophagy protein ATG5, which facilitates the conjugation of LC3 and related proteins to the autophagosome outer membrane(54). ULK1-dependent, ATG5-independent autophagy also occurs after DNA damage 58 , and is required for the efficient elimination of mitochondria during reprogramming of fibroblasts to induced . In the previous studies, ATG5-independent autophagy required the GTPase RAB9, probably for the trafficking of golgi vesicles to elongating autophagosomes. Further studies will be important to better understand the mechanisms of free -globin autophagy. Of particular interest will be to define the requirements for various autophagy-related proteins including 20 RAB9, and to elucidate the mechanisms that direct free -globin to autophagosomes. ULK1 is positively regulated by phosphorylation from AMPK and is inhibited by mTORC1-mediated phosphorylation (45, 57, 58) . We tested rapamycin as an ULK1 activator in β-thalassemia because it is an approved drug with a well-defined, manageable toxicity profile(47). Rapamycin or related drugs stimulate neuronal autophagy of pathological proteins in several experimental models for neurodegenerative disease(59) and improve RBC number in β-thalassemic mice (60) . Our findings extend the latter result by elucidating the definitive mechanism (ULK1-dependent autophagy of free -globin) and
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showing that rapamycin can reduce free -globin accumulation in human erythroblasts.
Specially, rapamycin treatment significantly reduced erythroblast accumulation of free -globin in a dose-dependent manner in TD β-thalassemic cells and almost fully eliminated free -globin in NTD β-thalassemic cells treated with the highest dose of rapamycin tested. In addition to stimulating autophagy, rapamycin treatment of cultured human 10 erythroblasts induces the synthesis of -globin, a fetal-expressed -like globin that can bind and detoxify free -globin(47). While this effect did not occur in our studies, probably due to differences in experimental design, rapamycin-induced -globin synthesis could synergize with enhanced -globin autophagy to further alleviate the pathophysiology of β-thalassemia. Of note, this hypothesis cannot be tested easily in mouse models for -15 thalassemia because fetal-expressed -globin genes exist only in humans and some nonhuman primates. Overall, we believe that the composite data now provide sufficient rationale for a clinical trial to test the effect of treatment with rapamycin or a newer analog on ineffective erythropoiesis and RBC longevity in β-thalassemia. Moreover, the identification of ULK1 as a major effector of clearance of free -globin identifies new 20 therapeutic targets, namely AMPK and ULK1 itself. The development of drugs that activate these kinases is underway (61, 62) , and their utility as potential therapies for β-thalassemia should be assessed. More generally, our findings should arouse new interest in the concept of therapeutic ULK activation to stimulate autophagy in other protein aggregation disorders.
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M , n = 12. All graphs show the mean ± SD; ****P < 0.0001; ***P < 0.001; **P < 0.01; *P < 0.05; ns: not significant. Western blot analysis for autophagic markers of reticulocytes from mice of indicated genotypes. All graphs show the mean ± SD; ***P < 0.001; *P < 0.05; ns: not significant. , n = 4. All graphs show the mean ± SD; ***P < 0.001; *P < 0.05; ns: not significant. , n = 4. All graphs show the mean ± SD; ****P < 0.0001; ***P < 0.001; **P < 0.01; ns: not significant versus vehicle for each genotype, respectively, by two-way ANOVA. mice after treatment with vehicle (n = 9) or rapamycin (n = 8).
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All graph shows the mean ± SD; ****P < 0.0001; ***P < 0.001; **P < 0.01; *P < 0.05; ns: not significant. ****P < 0.0001; **P < 0.01; ns: not significant. 
